标题
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook
作者
关键词
-
出版物
Journal of Hepatocellular Carcinoma
Volume Volume 9, Issue -, Pages 233-263
出版商
Informa UK Limited
发表日期
2022-03-30
DOI
10.2147/jhc.s358082
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
- (2022) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
- (2022) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
- (2021) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.
- (2021) Anthony B. El-Khoueiry et al. JOURNAL OF CLINICAL ONCOLOGY
- Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC).
- (2021) Mark Yarchoan et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells
- (2021) Simon J Dovedi et al. Cancer Discovery
- Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma
- (2021) Neehar D Parikh et al. Journal of Comparative Effectiveness Research
- Hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Disease Primers
- Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
- (2021) Philippe Rochigneux et al. Cancers
- Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis
- (2021) Ilario Giovanni Rapposelli et al. Cancers
- Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
- (2021) Chi-leung Chiang et al. JAMA Network Open
- Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
- (2021) A. Vogel et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy
- (2021) Alessandro Rizzo et al. Future Oncology
- Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
- (2021) Jeffrey Sum Lung Wong et al. Journal for ImmunoTherapy of Cancer
- Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α ‐fetoprotein: Outcomes by treatment‐emergent ascites
- (2021) Masatoshi Kudo et al. HEPATOLOGY RESEARCH
- Advances in immunotherapy for hepatocellular carcinoma
- (2021) Bruno Sangro et al. Nature Reviews Gastroenterology & Hepatology
- FDA Approval Summary: Nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib
- (2021) May Tun Saung et al. ONCOLOGIST
- Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
- (2021) Xin Zhang et al. JAMA Network Open
- Recent advances in immunotherapy for hepatocellular carcinoma
- (2021) Abid Ali Khan et al. Hepatobiliary & Pancreatic Diseases International
- Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma.
- (2021) Li Bai et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
- (2021) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
- (2021) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
- (2021) Masatoshi Kudo et al. JOURNAL OF HEPATOLOGY
- Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
- (2021) Zhenggang Ren et al. LANCET ONCOLOGY
- Limited efficacy of atezolizumab and bevacizumab for hepatocellular carcinoma previously treated with tyrosine kinase inhibitor
- (2021) Tomoharu Yamada et al. LIVER INTERNATIONAL
- Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives
- (2021) Yung-Yeh Su et al. SEMINARS IN LIVER DISEASE
- YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment
- (2021) Xiaochen Yang et al. Scientific Reports
- Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma
- (2021) Arndt Vogel et al. Liver Cancer
- Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
- (2021) Yuan-Hung Kuo et al. Frontiers in Oncology
- Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
- (2021) Arndt Vogel et al. Lancet Gastroenterology & Hepatology
- Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
- (2021) Yulei Wang et al. Experimental Hematology & Oncology
- Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: A focus on epithelial-mesenchymal transition
- (2021) Jia-jia Li et al. Journal of Integrative Medicine-JIM
- Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice
- (2021) David J. Pinato et al. EUROPEAN JOURNAL OF CANCER
- Systemic treatment of hepatocellular carcinoma: An EASL position paper
- (2021) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma
- (2021) Ruwanthi Kolamunnage-Dona et al. JOURNAL OF HEPATOLOGY
- Immunotherapies for hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma
- (2021) Yang Yang et al. Frontiers in Oncology
- CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma
- (2020) Yurong Gu et al. Aging-US
- A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
- (2020) Xiaoyu Li et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Ramucirumab: A Review in Hepatocellular Carcinoma
- (2020) Yahiya Y. Syed DRUGS
- Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2020) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117.
- (2020) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of locoregional therapies in the wake of systemic therapy
- (2020) Daniel H. Palmer et al. JOURNAL OF HEPATOLOGY
- Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
- (2020) Shukui Qin et al. LANCET ONCOLOGY
- Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
- (2020) Robin K. Kelley et al. ADVANCES IN THERAPY
- Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase 1 Trials
- (2020) Donghua Shi et al. CLINICAL CANCER RESEARCH
- Epidemiology of Hepatocellular Carcinoma
- (2020) Katherine A. McGlynn et al. HEPATOLOGY
- Erzhu Qinggan Jiedu Recipe improves the clinical outcome of hepatocellular Cancer after surgical resection: a case-control retrospective study
- (2020) Yang Cheng et al. INTERNAL MEDICINE JOURNAL
- Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
- (2020) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study
- (2020) Hyung‐Don Kim et al. LIVER INTERNATIONAL
- Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma?
- (2020) Yong Xie et al. TUMORI
- Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study
- (2020) Anthony Turpin et al. Clinics and Research in Hepatology and Gastroenterology
- Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study
- (2020) Won-Mook Choi et al. Cancers
- Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
- (2020) Cheol-Hyung Lee et al. Clinical and Molecular Hepatology
- Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma
- (2020) Furong Liu et al. Experimental Hematology & Oncology
- Icaritin‐induced immunomodulatory efficacy in advanced hepatitis B virus‐related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival
- (2020) Shu‐Kui Qin et al. CANCER SCIENCE
- Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a non-randomized, open-label, phase 2 trial
- (2020) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
- (2020) Petros Fessas et al. Journal for ImmunoTherapy of Cancer
- Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240
- (2020) Baek‐Yeol Ryoo et al. CANCER
- Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
- (2020) Eleonora Lai et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Systemic therapy of advanced hepatocellular carcinoma
- (2020) Peter R Galle et al. Future Oncology
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
- (2020) John D. Gordan et al. JOURNAL OF CLINICAL ONCOLOGY
- Kanglaite enhances the efficacy of cisplatin in suppression of hepatocellular carcinoma via inhibiting CKLF1 mediated NF-κB pathway and regulating transporter mediated drug efflux
- (2020) Chen Chen et al. JOURNAL OF ETHNOPHARMACOLOGY
- A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma
- (2020) Chun A. Changou et al. ONCOLOGIST
- Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice
- (2020) Jordi Rimola et al. EUROPEAN JOURNAL OF RADIOLOGY
- Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion
- (2020) Pablo Munoz-Schuffenegger et al. RADIOTHERAPY AND ONCOLOGY
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Child–Pugh Classification: Time to Abandon?
- (2019) Beverley Kok et al. SEMINARS IN LIVER DISEASE
- Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?
- (2019) Yun Huang et al. OncoTargets and Therapy
- Adoptive cell transfer therapy for hepatocellular carcinoma
- (2019) Renyu Zhang et al. Frontiers of Medicine
- Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy
- (2019) Chunfeng Qu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
- (2019) Shuang Qin et al. Journal of Hematology & Oncology
- Randomized phase II trial of sorafenib, capecitabine and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.
- (2019) Thomas Cheung Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).
- (2019) Max W. Sung et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
- (2019) Ahmed Omar Kaseb et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy
- (2019) Anthony Tanoto Tan et al. GASTROENTEROLOGY
- Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
- (2019) Michael Teufel et al. GASTROENTEROLOGY
- First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers
- (2019) Ying Fan et al. BMC CANCER
- Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
- (2019) Eric Assenat et al. BRITISH JOURNAL OF CANCER
- RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
- (2019) Shukui Qin et al. Future Oncology
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2019) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.
- (2019) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.
- (2019) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune cell therapy for hepatocellular carcinoma
- (2019) Eishiro Mizukoshi et al. Journal of Hematology & Oncology
- Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor Galunisertib ( LY 2157299) in Advanced Hepatocellular Carcinoma
- (2019) Sandrine Faivre et al. LIVER INTERNATIONAL
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
- (2019) MinKe He et al. JAMA Oncology
- O-022Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
- (2019) R Miksad et al. ANNALS OF ONCOLOGY
- LHX3 is an advanced-stage prognostic biomarker and metastatic oncogene in hepatocellular carcinoma
- (2019) Zhong-Lan You Cancer Biomarkers
- Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma
- (2019) Enrique Soto-Perez-de-Celis et al. Journal of the National Comprehensive Cancer Network
- Insights into the success and failure of systemic therapy for hepatocellular carcinoma
- (2019) Jordi Bruix et al. Nature Reviews Gastroenterology & Hepatology
- Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells
- (2019) Florian P. Reiter et al. CELLULAR ONCOLOGY
- Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
- (2019) M. Moehler et al. OncoImmunology
- Hepatotoxicity of immune check point inhibitors: Approach and management
- (2019) Ana Lleo et al. DIGESTIVE AND LIVER DISEASE
- Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies
- (2019) Alqahtani et al. Medicina-Lithuania
- A global view of hepatocellular carcinoma: trends, risk, prevention and management
- (2019) Ju Dong Yang et al. Nature Reviews Gastroenterology & Hepatology
- Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report
- (2019) Xin Chen et al. OncoTargets and Therapy
- Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma
- (2019) Ghassan K. Abou-Alfa et al. JAMA Oncology
- 755PAlpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial
- (2019) J Bruix et al. ANNALS OF ONCOLOGY
- 678PDOutcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
- (2019) L Rimassa et al. ANNALS OF ONCOLOGY
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
- (2019) Masaaki Kondo et al. BMC CANCER
- Lenvatinib Versus Sorafenib as First‐Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost–Utility Analysis
- (2019) John J. Kim et al. ONCOLOGIST
- Immunotherapy for hepatocellular carcinoma
- (2019) Yin Zongyi et al. CANCER LETTERS
- Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma
- (2019) Arndt Vogel et al. CANCER TREATMENT REVIEWS
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA-001Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)
- (2018) A Zhu et al. ANNALS OF ONCOLOGY
- Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: A randomized controlled study
- (2018) Xiao-feng Zhai et al. CANCER
- Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis
- (2018) Hong Zhu et al. CANCER RESEARCH
- Using Genome Sequence to Enable the Design of Medicines and Chemical Probes
- (2018) Alicia J. Angelbello et al. CHEMICAL REVIEWS
- Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients withRAS-mutated Hepatocellular Carcinoma
- (2018) Ho Yeong Lim et al. CLINICAL CANCER RESEARCH
- Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial
- (2018) Qian Chen et al. GUT
- Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
- (2018) Jorge A. Marrero et al. HEPATOLOGY
- The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study
- (2018) Yoshiyuki Wada et al. INTERNAL MEDICINE
- Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
- (2018) Richard S. Finn et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
- (2018) Lorenza Rimassa et al. LANCET ONCOLOGY
- Advances in studies of tyrosine kinase inhibitors and their acquired resistance
- (2018) Qinlian Jiao et al. Molecular Cancer
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
- (2018) Changhoon Yoo et al. Cancer Research and Treatment
- Combination Cancer Immunotherapy in Hepatocellular Carcinoma
- (2018) Masatoshi Kudo Liver Cancer
- A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
- (2018) Chia-Jui Yen et al. Liver Cancer
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up
- (2018) Jeong-Hoon Lee et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
- (2018) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Characteristics of Early Recurrence After Curative Liver Resection for Solitary Hepatocellular Carcinoma
- (2018) Sung-Mi Jung et al. JOURNAL OF GASTROINTESTINAL SURGERY
- The hepatocellular carcinoma market
- (2018) Joshua Dawkins et al. NATURE REVIEWS DRUG DISCOVERY
- Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma
- (2018) Masatoshi Kudo Liver Cancer
- Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
- (2018) Takayuki Kimura et al. CANCER SCIENCE
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- (2018) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Epidemiology and Management of Hepatocellular Carcinoma
- (2018) Laura Kulik et al. GASTROENTEROLOGY
- Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma
- (2018) Michael J Flynn et al. HEPATOLOGY
- Role of Endoglin (CD105) in the Progression of Hepatocellular Carcinoma and Anti-Angiogenic Therapy
- (2018) Aldona Kasprzak et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial
- (2018) Joong-Won Park et al. JOURNAL OF HEPATOLOGY
- Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma
- (2018) H. Degroote et al. Journal of Immunology Research
- Oncolytic virus immunotherapy: future prospects for oncology
- (2018) Junaid Raja et al. Journal for ImmunoTherapy of Cancer
- Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein−Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma
- (2017) Hidetoshi Nakagawa et al. GASTROENTEROLOGY
- Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma
- (2017) Rong-Ce Zhao et al. Hepatobiliary & Pancreatic Diseases International
- Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation
- (2017) Franco Trevisani et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
- (2017) Richard Jackson et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
- (2017) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Immunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies
- (2017) Anthony F. Daniyan et al. Nature Reviews Clinical Oncology
- Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data
- (2017) Sheng-Long Ye et al. TUMOR BIOLOGY
- Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated review
- (2017) Bao-Hong Yuan et al. Oncotarget
- Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma
- (2017) Jennifer Eatrides et al. Cancer Control
- T-cell receptor-engineered T cells for cancer treatment: current status and future directions
- (2017) Yu Ping et al. Protein & Cell
- Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study
- (2017) Jeong-Hoon Lee et al. OncoImmunology
- Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
- (2017) Abhishek D. Garg et al. OncoImmunology
- Lenvatinib in Advanced Hepatocellular Carcinoma
- (2017) Masatoshi Kudo Liver Cancer
- A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
- (2017) Masatoshi Kudo Liver Cancer
- Combination immunotherapy: a road map
- (2017) Patrick A. Ott et al. Journal for ImmunoTherapy of Cancer
- Does the underlying etiology of HCC effect outcome? A single-institution analysis.
- (2017) J. Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Selection of Patients with Hepatocellular Carcinoma for Sorafenib
- (2017) Ghassan K. Abou-Alfa Journal of the National Comprehensive Cancer Network
- The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation
- (2017) Matteo Ravaioli et al. Scientific Reports
- A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)
- (2016) W. M. Tai et al. ANNALS OF ONCOLOGY
- Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
- (2016) D. Koeberle et al. ANNALS OF ONCOLOGY
- Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
- (2016) Julien Bollard et al. GUT
- Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
- (2016) Ann-Lii Cheng et al. HEPATOLOGY
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- BIOSHARE multicenter neoadjuvant phase 2 study: Results of pre-operative sorafenib in patients with resectable hepatocellular carcinoma (HCC)—From GERCOR IRC.
- (2016) Mohamed Bouattour et al. JOURNAL OF CLINICAL ONCOLOGY
- Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study
- (2016) Michael Bitzer et al. JOURNAL OF HEPATOLOGY
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
- (2016) Jorge A. Marrero et al. JOURNAL OF HEPATOLOGY
- Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma
- (2016) A. R. Singh et al. MOLECULAR CANCER THERAPEUTICS
- Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival
- (2016) Omar Abdel-Rahman et al. Expert Review of Gastroenterology & Hepatology
- Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
- (2016) Yu Sawada et al. OncoImmunology
- Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges
- (2016) Li-Chun Lu et al. Liver Cancer
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma
- (2015) Eishiro Mizukoshi et al. CANCER LETTERS
- Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
- (2015) Joon Hyeok Lee et al. GASTROENTEROLOGY
- T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice
- (2015) Christina Dargel et al. GASTROENTEROLOGY
- Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma
- (2015) ZhengGang Ren et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient
- (2015) Waseem Qasim et al. JOURNAL OF HEPATOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- Immunological landscape and immunotherapy of hepatocellular carcinoma
- (2015) Jesús Prieto et al. Nature Reviews Gastroenterology & Hepatology
- Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma
- (2015) Longhao Sun et al. TUMOR BIOLOGY
- Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate
- (2015) Yaron Meirow et al. Frontiers in Immunology
- A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma
- (2015) Li Xu et al. OncoImmunology
- Targeting RTK Signaling Pathways in Cancer
- (2015) Tarik Regad Cancers
- PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment
- (2015) Wing Lam et al. Scientific Reports
- TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications
- (2014) Silvana C. Faria et al. ABDOMINAL IMAGING
- Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
- (2014) Q. Xiang et al. CLINICAL CANCER RESEARCH
- Oxaliplatin-based Chemotherapy: A New Option in Advanced Hepatocellular Carcinoma. A Systematic Review and Pooled Analysis
- (2014) F. Petrelli et al. CLINICAL ONCOLOGY
- Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies
- (2014) Anna Patrikidou et al. INVESTIGATIONAL NEW DRUGS
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
- (2014) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study
- (2014) S. Qin et al. ONCOLOGIST
- Staging systems of hepatocellular carcinoma: A review of literature
- (2014) Marcello Maida WORLD JOURNAL OF GASTROENTEROLOGY
- Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma
- (2014) Koichi Shimizu et al. Human Vaccines & Immunotherapeutics
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
- (2013) Maria Reig et al. HEPATOLOGY
- Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
- (2013) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Chinese herbal medicine-derived compounds for cancer therapy: A focus on hepatocellular carcinoma
- (2013) Yangyang Hu et al. JOURNAL OF ETHNOPHARMACOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Cytokine-induced killer cells promote antitumor immunity
- (2013) Jingting Jiang et al. Journal of Translational Medicine
- Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study
- (2013) G. Brandi et al. ONCOLOGIST
- The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis
- (2012) Joanne Chiu et al. CANCER
- Adjuvant therapy options following curative treatment of hepatocellular carcinoma: A systematic review of randomized trials
- (2012) J.-H. Zhong et al. EJSO
- Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
- (2012) FUJIMASA TADA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
- (2012) Chiun Hsu et al. JOURNAL OF HEPATOLOGY
- Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study
- (2012) Aziz Zaanan et al. JOURNAL OF HEPATOLOGY
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- TGFβ signalling in context
- (2012) Joan Massagué NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Feasibility of Gemcitabine plus Oxaliplatin in Advanced Hepatocellular Carcinoma Patients with Child-Pugh B Cirrhosis
- (2012) Marion Dhooge et al. ONCOLOGY
- Immunotherapeutic Approaches to Hepatocellular Carcinoma Treatment
- (2012) Alexander G. Miamen et al. Liver Cancer
- Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma
- (2011) L. Chen et al. EJSO
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Selective Recruitment of Regulatory T Cell through CCR6-CCL20 in Hepatocellular Carcinoma Fosters Tumor Progression and Predicts Poor Prognosis
- (2011) Kang-Jie Chen et al. PLoS One
- Adjuvant Therapy With Capecitabine Postpones Recurrence of Hepatocellular Carcinoma After Curative Resection: A Randomized Controlled Trial
- (2010) Yong Xia et al. ANNALS OF SURGICAL ONCOLOGY
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma
- (2010) Ghassan K. Abou-Alfa et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II Study of Oxaliplatin in Patients With Unresectable, Metastatic, or Recurrent Hepatocellular Cancer
- (2009) Y Yen et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
- (2009) Kristy J. Gotink et al. ANGIOGENESIS
- Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma
- (2009) J. O. Lee et al. ANNALS OF ONCOLOGY
- Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
- (2009) Sandrine Faivre et al. LANCET ONCOLOGY
- A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity
- (2008) J. R. Garlich et al. CANCER RESEARCH
- Recruitment and Activation of Natural Killer Cells In vitro by a Human Dendritic Cell Vaccine
- (2008) K. Gustafsson et al. CANCER RESEARCH
- A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma
- (2008) Daniel H. Palmer et al. HEPATOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation